Orchid Pharma Turns Profitable in Q2 FY27 as Net Profit Hits ₹28.6 Crore

Key numbers

Market Cap	₹5,296 CrMid Cap
P/E Ratio	611.05Sector PE: 43.74
Promoter Holding	74.45%Up 4.61% QoQ
RSI	47.66Neutral Zone

Key highlights

• Revenue from operations grew to ₹341 crore in Q2 FY27 from ₹298 crore in Q2 FY26
• Net profit reached ₹28.6 crore, compared to a net loss of ₹0.9 crore in the year-ago quarter
• Operating margins expanded significantly to 7.5% from 0.4% on a year-on-year basis
• Completed the amalgamation of Dhanuka Laboratories Limited with the company effective July 10, 2026
• Other income contributed ₹17.8 crore to the total income during the current quarter

Operational Integration Drives Revenue Growth

Orchid Pharma recorded consolidated revenue from operations of ₹341 crore for the September 2026 quarter, marking a 14.4% increase over the ₹298 crore reported in the corresponding quarter last year. This operational performance was supported by the successful integration of Dhanuka Laboratories Limited, which was sanctioned by the NCLT in June 2026 and became effective in July 2026. The accounting for this merger has been applied retrospectively from the appointed date of April 1, 2024.

Additionally, the company concluded the acquisition of Synmedic Laboratories' business on a going concern basis via a slump sale effective July 3, 2026.

Significant Expansion in Operating Margins

The company witnessed a sharp improvement in its profitability profile, with operating margins climbing to 7.5% in Q2 FY27 from a marginal 0.4% in Q2 FY26. Total income for the quarter stood at ₹359 crore, bolstered by ₹17.8 crore in other income, a substantial jump from ₹1.8 crore in the preceding June quarter. Profit before tax reached ₹26.8 crore, a significant rise compared to just ₹1.3 crore in the same period last year.

This margin expansion reflects the evolving scale of the pharmaceutical business following recent corporate restructuring and asset consolidations.

Full Utilization of QIP Proceeds

• Invested ₹135 crore in subsidiary OBPL for the Jammu manufacturing facility
• Allocated ₹195.46 crore for full or partial repayment of outstanding borrowings
• Deployed ₹0.36 crore for new block construction at the Alathur API facility
• Utilized ₹63.72 crore for general corporate purposes, including surplus funds
• Total net proceeds of ₹394.54 crore from the 2023 QIP fully exhausted as of September 30, 2026

Strategic Alliances and Future Outlook

Beyond financial restructuring, Orchid Pharma is focusing on market expansion and manufacturing capacity. On October 24, 2026, the company entered a 10-year exclusive licensing and supply agreement with Laboratorio Libra S.A. for its antibiotic Exblifep in nine Latin American countries.

Concurrently, the company is progressing with its ₹750 crore capex plan for the 7-ACA project, which is targeted for commissioning within FY27. These initiatives align with the management's earlier guidance of achieving 10% to 15% revenue growth in the base business with double-digit EBITDA margins for the full fiscal year.

What to watch next

• Commissioning of the 7-ACA project targeted for the remainder of FY27
• Expansion of Exblifep sales following the 10-year pact with Laboratorio Libra S.A.
• Next quarterly results announcement expected in February 2027

“The Scheme has an appointed date of April 01, 2024 and became effective on July 10, 2026 upon filing of the certified copy of the NCLT order with the Registrar of Companies, Chennai.”

Orchid Pharma · financial snapshot

Share price	₹884.4
Market capitalisation	₹5,296.25 Cr
Revenue (annual)	₹811.33 Cr
Net profit (annual)	₹20.55 Cr
Revenue (latest quarter)	₹304.17 Cr+28.01% vs previous quarter
Net profit (latest quarter)	₹3.22 Cr-86.44% vs previous quarter
P/E (TTM)	611.05×Sector 43.74×
Promoter holding	74.45%+4.61% QoQ
FII holding	0.93%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.